We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+75.05%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.24B
AUM Growth
+$266M
Cap. Flow
+$14.8M
Cap. Flow %
1.19%
Top 10 Hldgs %
58%
Holding
50
New
8
Increased
10
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SABS icon
SAB Biotherapeutics
SABS
+$25.8M
2
ABVX
Abivax
ABVX
+$22M
3
COGT icon
Cogent Biosciences
COGT
+$19.7M
4
DYN icon
Dyne Therapeutics
DYN
+$17.1M
5
LBRX
LB Pharmaceuticals
LBRX
+$12.7M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$125M
2
CMPS
Compass Pathways
CMPS
+$9.41M
3
IOBT
IO Biotech
IOBT
+$8.58M
4
CELC icon
Celcuity
CELC
+$8.15M
5
CTMX icon
CytomX Therapeutics
CTMX
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$154M 12.39%
2,278,203
-1,680,091
-42% -$125M
VRNA
2
DELISTED
Verona Pharma
VRNA
$149M 11.97%
1,393,432
– –
CDTX
3
DELISTED
Cidara Therapeutics
CDTX
$126M 10.11%
1,311,425
– –
TERN
4
DELISTED
Terns Pharmaceuticals
TERN
$51.8M 4.17%
6,895,746
– –
TRVI icon
5
Trevi Therapeutics
TRVI
$2.62B
$46.6M 3.75%
5,094,668
+606,765
+14% +$4.55M
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$41M 3.3%
2,684,109
– –
COGT icon
7
Cogent Biosciences
COGT
$6.95B
$40.1M 3.22%
2,789,137
+1,666,666
+148% +$19.7M
SVA
8
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 3.07%
5,903,000
– –
ORIC icon
9
Oric Pharmaceuticals
ORIC
$1.23B
$37.5M 3.02%
3,126,604
– –
GERN icon
10
Geron
GERN
$930M
$37.3M 3%
27,225,292
– –
CMPX icon
11
Compass Therapeutics
CMPX
$367M
$33.4M 2.69%
9,545,466
+3,502,000
+58% +$11.1M
DYN icon
12
Dyne Therapeutics
DYN
$4.28B
$33.1M 2.66%
2,614,960
+1,500,000
+135% +$17.1M
ABVX
13
Abivax
ABVX
$10.8B
$30.5M 2.45%
+359,305
New +$22M
DRUG
14
Bright Minds Biosciences
DRUG
$706M
$30.4M 2.45%
501,617
+250,045
+99% +$9.71M
TRML
15
DELISTED
Tourmaline Bio
TRML
$28.3M 2.28%
591,882
– –
ZBIO
16
Zenas BioPharma
ZBIO
$2.04B
$26.3M 2.11%
1,183,260
– –
VSTM icon
17
Verastem
VSTM
$547M
$23.4M 1.88%
2,644,985
+1,106,524
+72% +$8.23M
SABS icon
18
SAB Biotherapeutics
SABS
$264M
$23M 1.85%
+11,420,000
New +$25.8M
VRDN icon
19
Viridian Therapeutics
VRDN
$2.15B
$21.2M 1.71%
982,576
– –
AKRO
20
DELISTED
Akero Therapeutics
AKRO
$20.6M 1.66%
434,689
– –
ERAS icon
21
Erasca
ERAS
$6.3B
$20.2M 1.63%
9,273,428
+2,516,672
+37% +$4M
RZLT icon
22
Rezolute
RZLT
$474M
$19.9M 1.6%
2,112,432
– –
ACRS icon
23
Aclaris Therapeutics
ACRS
$744M
$16.9M 1.36%
8,888,888
– –
CRVS icon
24
Corvus Pharmaceuticals
CRVS
$1.12B
$16.5M 1.33%
2,234,566
– –
OLMA icon
25
Olema Pharmaceuticals
OLMA
$1.01B
$14.7M 1.19%
1,505,862
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Vivo Capital held 50 positions worth $1.24B, up 27% from $977M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Vivo Capital's Q3 2025 filing shows 8 new, 10 increased, 2 reduced and 3 closed positions. Its largest new stake was SAB Biotherapeutics: 11,420,000 shares worth $23M. The largest sale was Soleno Therapeutics, an estimated $125M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Vivo Capital's largest Q3 2025 buy was SAB Biotherapeutics: 11,420,000 shares worth $23M.
  • Vivo Capital added most to Cogent Biosciences in Q3 2025, an estimated $19.7M increase.
  • Vivo Capital's biggest Q3 2025 reduction was Soleno Therapeutics, cutting an estimated $125M.
  • Vivo Capital fully exited Compass Pathways in Q3 2025, selling an estimated $9.41M.
  • Vivo Capital's ten largest holdings make up 58% of its $1.24B portfolio in Q3 2025.
  • Vivo Capital opened 8 new positions and closed 3 in Q3 2025.
  • Vivo Capital's portfolio value rose 27% quarter-over-quarter to $1.24B.

Based on Vivo Capital's 13F filing for Q3 2025, filed 14 Nov 2025.